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Autologous hematopoietic cell transplantation (AHCT) as initial therapy of patients with multiple myeloma
(MM) improves survival. However, data to support this approach for relapsed/progressive disease after initial
AHCT (AHCT1) are limited. Using Center for International Blood and Marrow Transplant Research data, we
report the outcomes of 187 patients who underwent a second AHCT (AHCT2) for the treatment of relapsed/
progressive MM. Planned tandem AHCT was excluded. Median age at AHCT2 was 59 years (range, 28 to 72),
and median patient follow-up was 47 months (range, 3 to 97). Nonrelapse mortality after AHCT2 was 2% at 1
year and 4% at 3 years. Median interval from AHCT1 to relapse/progression was 18 months, and median
interval between transplantations was 32 months. After AHCT2, the incidence of relapse/progression at 1 and
3 years was 51% and 82%, respectively. At 3 years after AHCT2, progression-free survival was 13%, and overall
survival was 46%. In multivariate analyses, those relapsing 36 months after AHCT1 had superior
progression-free (P ¼ .045) and overall survival (P ¼ .019). Patients who underwent AHCT2 after 2004 had
superior survival (P ¼ .026). AHCT2 is safe and feasible for disease progression after AHCT1. In this retro-
spective study, individuals relapsing 36 months from AHCT1 derived greater beneﬁt from AHCT2 compared
with those with a shorter disease-free interval. Storage of an adequate graft before AHCT1 will ensure that the
option of a second autologous transplantation is retained for patients with relapsed/progressive MM.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION centers contribute to the registration data. Research data are collected on
Data support the use of autologous hematopoietic cell
transplantation (AHCT) in the up front treatment of eligible
patients with plasma cell multiple myeloma (MM). Pivotal
studies from the 1990s and 2000s demonstrated prolonged
remission and survival when AHCT was compared with
chemotherapy alone [1-3]. A beneﬁt in progression-free
survival (PFS) has been conﬁrmed in meta-analyses [4],
although the success of salvage therapy in the chemotherapy
arms likely mitigated demonstration of an overall survival
(OS) beneﬁt. Even in the era of novel agents, AHCT remains
a cornerstone of therapy [3,5-7].
When patients relapse/progress after an up front single or
tandem transplantation, salvage treatment options include
additional chemotherapy, clinical trials with investigational
agents, and, in select cases, allogeneic hematopoietic cell
transplantation, or a second autologous transplantation.
Although lenalidomide and bortezomib improve survival in
relapsed/progressive myeloma, the development of chemo-
therapy resistance is a common feature of this disease, and the
survival rate of patients refractory to both bortezomib and
lenalidomide is dismal [8].
Data regarding outcomes of a second AHCT (AHCT2)
performed as salvage therapy for relapse/progression after
AHCT1 are primarily limited to retrospective analyses from
single institutions [9-15]. Registry data have the advantage of
larger numbers of patients in a multi-institutional context.
With this in mind, we analyzed data from 187 patients re-
ported to the Center for International Blood and Marrow
Transplant Research (CIBMTR) to clarify the beneﬁts of
AHCT2, performed at relapse/progression after AHCT1.
METHODS
Data Source
The CIBMTR is a research afﬁliation of the International Bone Marrow
Transplant Registry (IBMTR), the Autologous Blood and Marrow Transplant
Registry (ABMTR), and the National Marrow Donor Program that comprises
a voluntary working group of more than 450 transplantation centers
worldwide that contribute detailed data on consecutive allogeneic HCT and
AHCT to a statistical center at the Health Policy Institute of the Medical
College of Wisconsin in Milwaukee or the National Marrow Donor Program
Coordinating Center in Minneapolis, Minnesota. Participating centers are
required to register all transplantations consecutively; compliance is moni-
tored by on-site audits. Patients are followed up longitudinally, with yearly
follow-up. Computerized checks for errors, physicians’ review of submitted
data, and on-site audits of participating centers ensure data quality. Obser-
vational studies conducted by the CIBMTR are performed with a waiver of
informed consent and in compliance with Health Insurance Portability and
Accountability Act regulations as determined by the institutional review
board and the privacy ofﬁcer of theMedical College ofWisconsin. All CIBMTRa subset of registered patients and include detailed disease and pre-
transplantation and post transplantation clinical information.
Patients
We identiﬁed 983 patients who underwent a second AHCT for MM
between 1995 and 2008. Patients who had AHCT2 for reasons other than
relapsed/progressive disease were removed from the study cohort,
including planned tandem transplantation (n ¼ 704), graft failure (n ¼ 10),
another malignancy (n ¼ 1), or unknown (n ¼ 23). Patients who had
undergone a previous allogeneic stem cell transplantation (n ¼ 10), a third
subsequent allogeneic stem cell transplantation (n ¼ 2), and those without
a minimum of 100 days of follow-up data (n ¼ 46) were also excluded. A
total of 187 patients from 55 centers in North America who received an
AHCT2 for relapsed/progressive MM after an initial AHCT1 comprised the
ﬁnal study population. Median follow-up of survivors from the second
transplantation in this study was 47 months (range, 3 to 97 months).
Statistical Methods
Outcomes analyzed included relapse/progression, nonrelapse mortality
(NRM), PFS, and OS. Relapse/progression was deﬁned according to the stan-
dard European Group for Blood and Marrow Transplantation/IBMTR/ABMTR
criteria [16]. NRM was deﬁned as death from any cause within the ﬁrst 28
days after transplantation or death thereafter in the absence of relapse/
progression. OS interval was deﬁned as the time from AHCT2 to death from
any cause. Patients alive without evidence of disease relapse/progression
were censored at last follow-up and the PFS event summarized by a survival
curve. Cumulative incidence of NRM and relapse/progressionwere calculated
using cumulative incidence curves to accommodate competing risks. Asso-
ciations between patient-, disease-, and transplantation-related factors and
survival were assessed using multivariate Cox proportional hazards regres-
sion. The variables considered in the multivariate analysis were age
(continuous), sex, Karnofsky performance score, Durie-Salmon stage, and
immunochemical subtype of MM, disease status before AHCT2, conditioning
regimen for AHCT2 (melphalan alone versus others), interval from AHCT1 to
relapse/progression, interval from AHCT1 to AHCT2, and the year of AHCT2.
Forward stepwise variable selection at a .05 signiﬁcance level was used
to identify covariates. In the model, the assumption of proportional hazards
was tested for each variable using a time-dependent covariate and graphical
methods. All variables considered in the multivariate analysis satisﬁed the
proportionality assumption. All computations were made using the statis-
tical package SAS version 9.1 (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Patient characteristics are summarized in Table 1. The
median age of the cohort was 59 years at AHCT2 (range, 28
to 74), and 53% were of Karnofsky performance score 90.
Most patients (78%, n ¼ 146) were white. Median interval
from AHCT1 to AHCT2 was 32 months (range, 6 to 122
months) and from AHCT1 to ﬁrst relapse/progression was 18
months (range, 3 to 121 months). A total of 22 patients
(12%) underwent the second transplantation within 12
Table 1
Characteristics of Patients Receiving AHCT2 for Relapsed/Progressive MM
between 1995 and 2008
Patient Characteristics First
Transplantation
Second
Transplantation
Demographics
Number of patients 187 187
Age at transplantation,
median (range), yr
57 (28-72) 59 (28-74)
Male sex 118 (63%)
Race
White 146 (78%)
African American 23 (12%)
Other 18 (10%)
Disease related
Immunochemical subtype
of MM
IgG 89 (48%)
IgA 37 (20%)
Light chain/other/unknown 61 (33%)
Durie-Salmon stage at diagnosis
Stage I 12 (6%) d
Stage II 40 (21%) d
Stage III 111 (59%) d
Missing 24 (13%) d
International stage at diagnosis
Stage I 34 (18%) d
Stage II 26 (14%) d
Stage III 17 (9%) d
Missing 110 (59%) d
Karnofsky score before AHCT2
90% 99 (53%)
Transplantation related
Serum albumin before AHCT
<3.5 g/L 49 (26%) 59 (32%)
Serum creatinine before
transplantation
1.5 mg/dL 13 (7%) 25 (13%)
Conditioning regimen for
transplantation
Melphalan alone 149 (80%) 158 (84%)
Melphalan þ TBI  others 10 (5%) 4 (2%)
Melphalan  others 9 (5%) 17 (9%)
TBI (no melphalan)  others 5 (3%) 2 (1%)
Busulfan þ cyclophosphamide 
others
12 (6%) 5 (3%)
Others 2 (1%) 1 (<1%)
Disease status before
transplantation
CR/PR 153 (82%) 74 (40%)
MR/NR/SD 21 (11%) 86 (46%)
Relapse/progression 1 (<1%) 27 (14%)
Missing 12 (6%) d
Cytogenetics at any time before
transplantation
Abnormal d 27 (14%)
Normal d 84 (45%)
Not assessable/unknown d 76 (41%)
Time from AHCT1 to AHCT2,
median (range), mo
d 32 (6-122)
6-12 d 22 (12%)
12-23 d 36 (19%)
24-35 d 51 (27%)
36 d 78 (42%)
Time from AHCT1 to relapse/
progression, median
(range), mo
18 (3-121) d
<6 33 (18%) d
6-11 27 (14%) d
12-23 55 (29%) d
24-35 36 (19%) d
36 36 (19%) d
(continued)
Table 1
(continued)
Patient Characteristics First
Transplantation
Second
Transplantation
Year of transplantation
1990-1994 7 (4%) d
1995-2000 50 (27%) 18 (10%)
2001-2002 50 (27%) 18 (10%)
2003-2004 38 (20%) 35 (19%)
2005-2006 36 (19%) 53 (28%)
2007-2008 6 (3%) 63 (34%)
Post transplantation
Best response reported after
AHCT
CR 81 (43%) 47 (25%)
PR 73 (39%) 81 (43%)
MR 6 (3%) 11 (6%)
NR/SD 20 (11%) 30 (16%)
Progression 5 (3%) 18 (10%)
Missing 2 (1%) d
Maintenance therapy
None d 143 (71)
Imid (lenalidomide,
thalidomide)
d 22 (11)
Interferon/interleukin-2 d 14 (7)
Steroid d 10 (5)
Bortezomib d 9 (5)
Others (cyclophosphamide,
melphalan)
d 3 (2)
Median follow-up of survivors,
(range), mo
d 47 (3-97)
CR indicates complete response; PR, partial response; MR, minimal
response; NR, no response; SD, stable disease; TBI, total body irradiation.
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less likely to be in complete or partial remission before
AHCT2.Peripheral blood progenitor cell grafts were collected
before AHCT1 in all patients, and no use of remobilized
grafts after AHCT1 was reported. High-dose melphalan was
used as a preparative regimen in 84%, whereas the use of
total body irradiationebased regimens was minimal (3%).
The number of reported salvage AHCT2 increased within
the time frame of the collected data: 18 transplantations
each were reported during the years 1995 to 2000 and
2001 to 2002, 35 transplantations occurred during 2003 to
2004, 53 transplantations were recorded during 2005 to
2006, and 63 transplantations occurred during 2007 to
2008.Safety and Relapse
Figure 1 shows the cumulative incidence of NRM and
relapse/progression. The incidence of NRM after AHCT2
was 2% (95% conﬁdence interval [CI], 1%-5%) at 1 year and
4% (95% CI, 2%-8%) at 3 years, respectively. Of the 187
patients, 10 died from NRM, including infection (n ¼ 4),
organ failure (n ¼ 4), and second malignancy (n ¼ 2). The
two reported second malignancies were breast cancer and
myelodysplastic syndrome. Engraftment rate of neutrophils
(absolute neutrophil count 500/mm3 for 3 subsequent
days) and platelets (platelet count 20,000/mm3 for 7
subsequent days without platelet transfusion) at 28 days
was 96% (range, 93% to 98%) and 88% (range, 83% to 92%),
respectively.
Cumulative incidence of relapse/progression after AHCT2
is shown in Figure 1. Incidence of relapse/progression was
51% (95% CI, 43%-58%) at 1 year, 82% (95% CI, 76%-88%) at 3
years, and 91% (95% CI, 85%-95%) at 5 years. In multivariate
analysis (Table 2), a longer interval from AHCT1 to initial
relapse (36 months) was associated with a lower risk of
Figure 1. Cumulative incidence of relapse/progression and NRM after salvage
AHCT2.
Figure 2. Probability of PFS and OS after AHCT2.
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.49-.97). In individuals with a greater than 36-month interval
between AHCT1 and initial relapse/progression, the inci-
dence of relapse/progression was 41% (95% CI, 25%-57%) at 1
year, 68% (95% CI, 51%-82%) at 3 years, and 81% (95% CI, 65%-
93%) at 5 years after AHCT2.PFS and OS
The 1-, 3-, and 5-year PFS after AHCT2 was 47% (95% CI
40% to 54%),13% (95% CI 9% to 19%), and 5% (95% CI 2% to 11%),
respectively. The OS at 1 year was 83% (95% CI, 77%-89%),
whereas it was 46% (95% CI, 37%-54%) and 29% (95% CI,
21%-38%) at 3 and 5 years, respectively (Figure 2). In multi-
variate analysis, a longer interval from AHCT1 to relapse/
progression (36 months) was associated with superior PFS
and OS (Figure 3). For those relapsing 36 months after
AHCT1, the PFS at 1, 3, and 5 years was 59% (95% CI, 41%-74%),
26% (95% CI,13%-41%), and 13% (95% CI, 4%-28%), respectively.
Corresponding OS was 88% (95% CI, 71%-95%) at 1 year, 58%
(95% CI, 39%-73%) at 3 years, and 48% (95% CI, 28%-65%) at 5
years. OS stratiﬁed by the time from AHCT1 to relapse/
progression is shown in Figure 3. AHCT2 performed after
2004 was associated with superior survival (relative risk, .61;
95% CI, .4-.94).DISCUSSION
AHCT is used as an up front or salvage treatment for
patients with MM [17]. AHCT2 has also been used to salvageTable 2
Multivariate Analysis of Risk Factors for Relapse/Progression, Treatment
Failure (Inverse of PFS), and OS
Outcome n HR 95% CI P Value
Relapse/progression
Time from AHCT1 to REL
36 mo 36 1
<36 mo 151 1.58 (1.03-2.41) .036
Treatment failure/PFS
Time from AHCT1 to REL
36 mo 36 1
<36 mo 151 1.52 (1.01-2.30) .045
Overall mortality/survival
Time from AHCT1 to REL
36 mo 36 1
<36 mo 151 1.91 (1.12-3.28) .019
Year of AHCT2
1995-2004 100 1
2005-2008 87 .61 (.40-.94) .026
HR indicates hazard ratio; REL, Relapse.patients relapsing after an initial (up front) AHCT [18].
Current National Comprehensive Cancer Network guidelines
recommend that AHCT-eligible patients with MM undergo
leukopheresis with the intent to collect enough peripheral
blood progenitor cell to undergo two AHCTs, in which case
the second graft can be cryopreserved for use as salvage
AHCT2 [17].
There is considerable heterogeneity in practice patterns,
and no current standard of care exists as to whether or when
to implement ACHT2 for relapsed/progressive myeloma.
ACHT2 is a distinct treatment strategy compared with
tandem AHCT, which is deﬁned as two planned cycles of
high-dose therapy with peripheral blood progenitor
cell support in which a second AHCT is performed within
180 days of the ﬁrst, with the objective of increasing
the likelihood of a complete or very good partial remission
[19]. Inconsistent results have been reported by the
studies randomizing patients to single versus tandem AHCT
[19-22]. The most recent National Comprehensive Cancer
Network guidelines are not prescriptive regarding tandem
transplantation [17].
Notably, many third-party payers, including Centers for
Medicare and Medicaid Services in the United States, reim-
burse for a single AHCT only (National coverage determina-
tion for stem cell transplantation, Centers for Medicare and
Medicaid Services, Manual section number 110.8.1. http://
www.cms.gov/medicare-coverage-database. Accessed 4/30/
2012).
Our data provide an estimate of the effectiveness of
AHCT2 as salvage therapy in a select group of patients andFigure 3. Probability of OS after AHCT2 stratiﬁed by time to relapse/
progression from AHCT1.
Table 3
Comparison of Our Data with the Major Studies That Evaluated Outcome of Second Salvage AHCT for Myeloma
CIBMTR (our data) Toronto/Princess
Margaret [10]
MD Anderson [14] University of
Pennsylvania [12]
S. Texas VA [9] Germany [15]
Year published 2011 2011 2009 2009 2011
Number of patients 187 81 44 41 25 55
Years inclusive 1995-2008 1992-2009 1992-2008 1998-2007 1999-2007 1993-2008
Interval between
ASCT1 and ASCT2
(range)
32 (6-122) NR 30 (2-78) 37 (3-91) 39 (4-74)
Post-ASCT outcomes
CR 25% 7.7% 20% 9%
CR/VGPR 11% 16% (6/38 cases) 9%
VGPR 39.7%
PR 43% 50% 79% 44% 56%
ORR 97% (day 100) 90% 55% (21/38 cases) 64% 85%
NRM 4% (5 yr) 2.6% (100 days) 2% (100 days) 7% (100 d) 8% 5% (100 d)
Median PFS post AHCT2, mo 11.2 16.4 12.3 8.5 12 EFS: 14
Median OS post AHCT2, mo 30 53 31.7 20.7 19 52
Multivariate analysis Improved OS if
interval between
AHCT1 relapse
36 mo and for
AHCT2 after 2004
Improved PFS and
OS if interval
between AHCT1
and AHCT2
>24 mo
Worse OS associated
with AA race, shorter
TTP after AHCT1, IgG,
and increased number
of prior therapies
Worse outcomes
if >4 prior
therapies, TTP
after AHCT1
12 mo
NR Improved
outcomes
if remission
>12 mo after
AHCT1
VA indicates Veterans Administration; CR, complete response; VGPR, very good partial response; PR, partial response; EFS, event-free survival; AA, African
American; TTP, time to progression; IgG, immunoglobulin G; NR, not recorded.
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rates are similar to up front AHCT in reported studies
[20,23,24] and previously reported rates after second salvage
transplantation [9-15]. About 29% of patients were alive at 5
years, and 25% of these pretreated patients achieved
a complete remission after AHCT2. Thus, AHCT2 at ﬁrst
relapse/progression may harness the advantage of durable
remission and preserves the option of using other therapies
for subsequent relapses/progressions.
We summarize in Table 3 some of the comparable pub-
lished retrospective analyses of salvage autologous trans-
plantation in patients with MM [9,10,12,14,15]. The most
consistent ﬁnding among these studies is that a longer
progression-free interval after AHCT1 predicts improved
survival after AHCT2. In our analysis, patients progressing
later than 36 months after AHCT1 had a median OS after
AHCT2 of 49 months (95% CI, 34-108) compared with
a median OS of 28 months (95% CI, 24-42) in patients who
had a shorter progression-free interval after AHCT1. Other
published retrospective studies summarized in Table 3 have
correlated better outcomes in patients who relapse/progress
more than 2 years after ACHT19,10,12,15. It may be that
patients who relapse/progress within 2 to 3 years of AHCT1
would be better served by participation in clinical trials
rather than a second high-dose melphalan AHCT, although
conﬁrmation of this hypothesis would require a randomized
study.
Aiming to understand the optimal timing of a second
autologous transplantation, researchers with the European
Group for Blood andMarrow Transplantation looked at 7,452
patients, of which 2,655 had an up front planned AHCT2, and
4,797 had unplanned AHCT2 in the years between 1993 and
2002. They found superior outcomes when AHCT2 was per-
formed before relapse (within 6 to 12months of AHCT1) [25].
In this study, the median OS (from AHCT1) of the unplanned
AHCT2 was 51months. This is not to be confused with our OS
of 30 months from AHCT2. This is one of the largest retro-
spective studies addressing the timing of a second trans-
plantation, but it was performed before the advent of novelagents and aims to answer a different question from that
proposed here.
In our multivariate analyses, disease status and chemo-
therapy sensitivity before AHCT2 did not affect outcomes,
because at the time of AHCT2, 46% of patients were in less
than a partial remission. Given that the cohort spans 15
years, these data were largely accumulated before the rela-
tively recent era of maintenance therapy after AHCT1.
Recently published, high-quality, prospective data demon-
strate improvement in PFS and OS when lenalidomide is
initiated after AHCT1 [26,27]. Given that the use of novel
agents as maintenance therapy improve PFS after AHCT1, it is
likely that in the modern era, a greater proportion of
relapses/progressions after AHCT1 may be beyond the 36-
month interval identiﬁed. It is unclear whether the same
beneﬁts of AHCT2 would be preserved in patients who
receive maintenance after AHCT1. Survival has improved
since 2004, although NRM and PFS after AHCT2 were not
different. We hypothesize that the improved OS seen in
patients who underwent transplantation after 2004 is due to
the use of novel agents in treatment of relapse/progression
after AHCT2.
MM is as twice as common among African Americans
than white Americans [28]. In the US population, about 13%
of individuals identify themselves in census rolls as African
American/black [29]. The percentage of African Americans
who underwent AHCT2 in our study is 12%dwhich is less
thanwhat might be expected. Previous analyses have shown
that African Americans are less likely to have access to
AHCT1 as a treatment for MM [30], although the outcome
after AHCT is similar among blacks and whites [31]. The
reasons for this disparity are unclear and probably
multifactorial.
Limitations inherent to our analyses include its retro-
spective nature and incomplete data on maintenance
therapy and on modern prognostic factors, such as cytoge-
netics and International Staging System (ISS) stage. These
limitations are because the reported time period predates
newer maintenance therapies, ISS staging, and risk
L.C. Michaelis et al. / Biol Blood Marrow Transplant 19 (2013) 760e766 765stratiﬁcation. Information about new cytogenetic or molec-
ular characteristics of disease at the time of AHCT2 was
unavailable. Retrospective data collection also meant that
the dataset includes only patients who actually received an
AHCT2. We were not able to determine the characteristics of
patients whowere excluded on the basis of nonavailability of
a graft or other factors such as rapid relapse/progression,
poor performance status, age, insurance status, comorbid-
ities, or patient/provider preference. This may account for
the relatively low numbers of overall AHCT2 recorded by the
registry, and it limits the applicability of the ﬁndings
compared with prospective data. All AHCT2 were performed
using hematopoietic cells collected and stored before
AHCT1 and is consistent with current clinical practice
recommendations.
These data provide support for the use of late second
AHCT in patients with relapsed/progressive MM. We also
underscore the need for randomized studies looking at
therapies after relapse/progression comparing available
options, including AHCT2, chemotherapy combinations, and
allogeneic transplantations. One particular unmet need is
identifying investigational strategies in patients who have
early progression after AHCT1: Do these individuals beneﬁt
from newer induction or conditioning regimens? An ongoing
phase III clinical trial (myeloma X) in the United Kingdom
enrolls patients who relapse/progress at least 18 months
after AHCT1 to receive reinduction with bortezomib, doxo-
rubicin, and dexamethasone and randomizes them to AHCT2
versus low-dose maintenance cyclophosphamide (see
www.clinicaltrials.gov, NCT00747877). Prospective clinical
trials like these are needed to deﬁne the risk-to-beneﬁt ratio
as well as the placement and sequencing of AHCT2 relative to
other therapies.ACKNOWLEDGMENTS
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